Stanker James H 4

4 · Processa Pharmaceuticals, Inc. · Filed Aug 2, 2024

Form 4

Period: 2024-04-05

Chief Financial Officer

Transactions

Award
Restricted Stock Units
2024-06-28+385→ 29,547 total
Exercise: $0.00→ Common Stock (385 underlying)
Award
Restricted Stock Units
2024-06-28+2,307→ 28,777 total
Exercise: $0.00→ Common Stock (2,307 underlying)
Award
Restricted Stock Units
2024-06-28+385→ 29,162 total
Exercise: $0.00→ Common Stock (385 underlying)
Exercise/Conversion
Common Stock
2024-04-05+1,675→ 6,638 total
Tax Payment
Common Stock
2024-04-05$2.79/sh−518$1,445→ 6,120 total
Tax Payment
Common Stock
2024-07-10$1.71/sh−282$482→ 6,482 total
Exercise/Conversion
Common Stock
2024-07-10+644→ 6,764 total
Award
Restricted Stock Units
2024-06-28+3,077→ 26,470 total
Exercise: $0.00→ Common Stock (3,077 underlying)

Footnotes (4)

[F1]Distribution of vested restricted shares.
[F2]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
[F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
[F4]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Documents

1 file